Systemic sclerosis & Raynaud's
Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment
Study context
- Population
- Systemic sclerosis (SSc); drugs currently in phase 2 and phase 3 trials
- Outcome
- Emerging treatments
Main finding
As reported in the abstract
- Among emerging treatments, cellular therapies, including chimeric antigen receptor T-cell therapy, represent a significant innovation
Original publication
Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment. Ann Rheum Dis. Published 23 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →